


Healthcare Industry News: HIV/AIDS
News Release - October 2, 2006
Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT)
Source: Merck
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
